The University of Chicago Header Logo

Connection

Richard A. Larson to Drug Administration Schedule

Back to Details
This is a "connection" page, showing publications Richard A. Larson has written about Drug Administration Schedule.
Richard A. Larson
Connection Strength
1.329
Drug Administration Schedule
  1. Treatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract. 2018 11; 14(11):649-657.
    View in: PubMed
    Score: 0.141
  2. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 01; 31(7):923-9.
    View in: PubMed
    Score: 0.093
  3. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010 Oct 10; 28(29):4500-6.
    View in: PubMed
    Score: 0.080
  4. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home. Leuk Lymphoma. 2009 Jun; 50(6):868-70.
    View in: PubMed
    Score: 0.074
  5. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 01; 104(7):1442-52.
    View in: PubMed
    Score: 0.057
  6. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.
    View in: PubMed
    Score: 0.053
  7. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk Lymphoma. 2003 Jan; 44(1):39-48.
    View in: PubMed
    Score: 0.047
  8. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003 Jan 01; 101(1):6-14.
    View in: PubMed
    Score: 0.046
  9. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2001 Apr; 41(3-4):297-307.
    View in: PubMed
    Score: 0.042
  10. Dose-intensive therapy for adult acute lymphoblastic leukemia. Semin Oncol. 1999 Feb; 26(1):6-20.
    View in: PubMed
    Score: 0.036
  11. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559.
    View in: PubMed
    Score: 0.036
  12. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617.
    View in: PubMed
    Score: 0.036
  13. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998 May; 12(5):660-5.
    View in: PubMed
    Score: 0.034
  14. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017 09; 178(6):906-913.
    View in: PubMed
    Score: 0.032
  15. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 01 26; 129(4):424-447.
    View in: PubMed
    Score: 0.031
  16. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol. 1996 Jan; 14(1):188-95.
    View in: PubMed
    Score: 0.029
  17. Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016 Feb; 91(2):199-204.
    View in: PubMed
    Score: 0.029
  18. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10; 33(35):4167-75.
    View in: PubMed
    Score: 0.029
  19. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995 Apr 15; 85(8):2025-37.
    View in: PubMed
    Score: 0.028
  20. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015 Jan; 16(1):57-66.
    View in: PubMed
    Score: 0.027
  21. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res. 2014 Mar; 38(3):329-33.
    View in: PubMed
    Score: 0.025
  22. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013 May 02; 121(18):3703-8.
    View in: PubMed
    Score: 0.024
  23. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep; 12(9):841-51.
    View in: PubMed
    Score: 0.021
  24. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
    View in: PubMed
    Score: 0.019
  25. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10; 27(35):6041-51.
    View in: PubMed
    Score: 0.019
  26. Hypersensitivity reaction to high-dose cytarabine. Br J Haematol. 1989 Oct; 73(2):274-5.
    View in: PubMed
    Score: 0.019
  27. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009 Dec; 94(12):1669-75.
    View in: PubMed
    Score: 0.019
  28. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009 Feb 01; 115(3):551-60.
    View in: PubMed
    Score: 0.018
  29. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93.
    View in: PubMed
    Score: 0.018
  30. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. Blood. 1988 Oct; 72(4):1333-9.
    View in: PubMed
    Score: 0.018
  31. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834-9.
    View in: PubMed
    Score: 0.017
  32. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005 Nov; 29(11):1253-7.
    View in: PubMed
    Score: 0.014
  33. High-dose Ara-C plus VM-26 in adult acute lymphoblastic leukemia. Eur J Cancer Clin Oncol. 1985 Oct; 21(10):1261-3.
    View in: PubMed
    Score: 0.014
  34. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005 Jun 01; 11(11):4176-81.
    View in: PubMed
    Score: 0.014
  35. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol. 2005 May 20; 23(15):3404-11.
    View in: PubMed
    Score: 0.014
  36. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
    View in: PubMed
    Score: 0.013
  37. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15; 22(6):1087-94.
    View in: PubMed
    Score: 0.013
  38. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia. 2003 Feb; 17(2):323-7.
    View in: PubMed
    Score: 0.012
  39. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res. 2002 Sep; 8(9):2812-9.
    View in: PubMed
    Score: 0.012
  40. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001 Aug 15; 19(16):3611-21.
    View in: PubMed
    Score: 0.011
  41. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
    View in: PubMed
    Score: 0.007
  42. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. Bone Marrow Transplant. 1992 Jan; 9(1):41-7.
    View in: PubMed
    Score: 0.006
  43. High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study. Am J Hematol. 1986 Oct; 23(2):131-4.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.